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Pharmacologic reduction of 
sympathetic drive increases platelet 
alpha-2receptor number 
Several lines of evidence implicate sympathetic nervous system involvement in the pathophysiology of 
essential hypertension in man. Extrapolations are frequently made from in vitro measurements of plasma 
catecholamine levels to the physiologic role of the sympathetic system in hypertension. We assessed the 
utility and validity of such extrapolation from in vitro to in vivo measures of adrenergic function. Addition 
of g-uanadrel to diuretic therapy in 11 patients with essential hypertension reduced supine intra-arterial 
blood pressure from 135 ± 14/76 ± 9 to 127 ± 13/67 ± 5 mm Hg (P < 0.02). Supine heart rate was 
also reduced, from 77 ± 14 to 63 ± 13 bpm (P < 0.001). Plasma norepinephrine levels fell from 
303 ±.- 107 to 170 ± 46 pg/ml (P <0.01). Platelet a,-receptor number ([311]yohimbine maximal binding) 
increased from 204 ± 77 to 301 -± 150 fmol/mg (P < 0.02). The pupillary mydriatic response to 
phenylephrine and the forearm arterial vasoconstrictor response to intra-arterial norepinephrine did not 
change. Thus guanadrel reduced blood pressure by decreasing sympathetic tone. In this milieu of low 
sympathetic activity the platelet «,-receptor number increased, but physiologic responses to exogenous 
a-agonists did not change. Caution is therefore advised when extrapolating from in vitro measurement 
of plasma catecholamine levels and platelet a,-receptor number to the in vivo physiologic significance. 
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A number of investigators have identified an impor- 
tant pathophysiologic role for the sympathetic nervous 
system in essential hypertension in man. Studies in our 
laboratory showed a crucial role for the adrenergic sys- 
tem in maintaining the elevated cardiac output and heart 
rate in borderline hypertension.' Despite normal cardiac 
output, patients with elevated plasma renin activity and 
either borderline or mild hypertension maintained a 
higher blood pressure through increased neurogenic va- 
soconstriction.23 Other investigators reported increased 
pressor responsiveness to exogenous norepinephrine, 
but normal responses to angiotensin, in both borderline 
and established essential hypertension.45 Studies eval- 
uating local vascular responses also showed a similar 
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heightened sensitivity to both exogenous and endoge- 
nous norepinephrine .7 
Because of the potential importance of the adrenergic 
system in essential hypertension, methods for precise 
evaluation of sympathetic function would be useful. 
Plasma catecholamine levels are the most frequently 
measured index of sympathetic activity. Physiologic 
significance is then often extrapolated from measured 
catecholamine levels. We wished to evaluate the validity 
of extrapolating from the in vitro to the in vivo adren- 
ergic environment. In this study, guanadrel sulfate (Hy- 
lorel; Pennwalt Pharmaceuticals), which inhibits nor- 
adrenaline storage in and release from the sympathetic 
nerve terminal, was added to diuretic monotherapy in 
patients with essential hypertension. With this altered 
adrenergic environment we wanted to answer the fol- 
lowing questions: (a) Would plasma catecholamine 
levels (a frequent index of sympathetic drive) fall during 
guanadrel therapy? (b) Would platelet arreceptor num- 
ber change during therapy with a drug that reduces 
sympathetic drive? (c) Would sensitivity to exogenous 
catecholamines increase? (d) Would in vitro measures 
of sympathetic function (plasma catecholamines and 
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Table I. Comparison of supine baseline* 
hemodynamic and biochemical data before and after 
addition of guanadrel to diuretic monotherapy 
HR = Heart rate; SBP = intra-arterial systolic blood pressure; DBP = 
intra-arterial diastolic blood pressure; FABF = forearm blood flow; NE = 
norepinephrine; E = epinephrine; PRA = plasma renin activity; Al = 
angiotensin I. 
*After 30 minutes of rest. 
platelet a2-receptors) correlate with in vivo measure- 
ments of a-adrenergic physiologic responses in the fore- 
arm and pupil? 
METHODS 
Subjects. Eleven white patients (10 men and one 
woman) between 28 and 50 years old (X ± SD = 
36 ± 6 years) who were receiving diuretic monother- 
apy with suboptimally controlled casual blood pres- 
sure (>140 mm Hg systolic or >90 diastolic mm Hg 
in the office or >130 systolic or >85 diastolic at home) 
were enrolled. Subjects underwent complete history, 
physical, and routine laboratory examinations before 
entry into the study. All were healthy except for mild 
hypertension. They signed a written, informed consent 
form approved by the Hospital Committee for Human 
Research. 
Study design. The guanadrel study was an open- 
label, nonrandomized evaluation of physiologic and 
biochemical variables before and again 3 weeks after 
the start of guanadrel sulfate therapy. After the first 
study, guanadrel was begun at 5 mg twice a day for the 
first 5 to 7 days. If blood pressures measured at home 
had not fallen to <130/85 mm Hg or by 10 mm Hg, 
the dosage was increased to 10 mg twice a day. Eight 
subjects achieved the target blood pressure level with 
guanadrel, 10 mg/day, in addition to their diuretic. Of 
the three remaining subjects, one received guanadrel, 
5 mg twice a day, another took 15 mg twice a day, 
and a third took 30 mg twice a day. Subjects received 
the final dose of guanadrel 3 hours before each phys- 
iologic study. 
Measurements. Blood pressure was measured first 
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by mercury and cuff sphygmomanometry and subse- 
quently in intra-arterial recordings. 
Forearm blood flow was measured by venous occlu- 
sion, strain gauge plethysmography. The D. E. Hok- 
anson, Inc. EC-3 plethysmograph and E-10 rapid cuff 
inflator were connected to the polygraph and recorder 
as described below. 
The method for pupillary measurement has been de- 
scribed in detail.' In brief, pupil size was recorded with 
a binocular pupillograph for 30 seconds under stan- 
dardized lighting conditions. Thirty measurements of 
pupil size during the final 3 seconds were averaged both 
before and 1 hour after phenylephrine dosing. The in- 
crease in size of the right pupil (1% phenylephrine was 
always instilled into the right eye) minus the change in 
the size of the control (left) pupil equalled the mydriatic 
response to 1% phenylephrine at 1 hour. 
Plasma catecholamine 1° and plasma renin activity" 
assays were performed as previously described. To de- 
termine platelet membrane preparation and 131-11yo- 
himbine binding, 50 ml venous blood was immediately 
mixed with 1/9 volume of ACD (0.8 gm citric acid, 
2.2 gm trisodium citrate, and 2.45 gm dextrose per 100 
m1). After centrifugation for 7 minutes at 200 x g, the 
platelet-rich plasma was adjusted to pH 6.5 and cen- 
trifuged for 15 minutes at 2000 x g. The platelet pellet 
was resuspended in buffer (150 mmol/L NaC1, 1 mmol/ 
L EDTA, and 20 mmol/L TrisC1 at pH 7.6) and cen- 
trifuged again. The pellet was suspended in 10 ml ho- 
mogenization buffer (10 mmol/L TrisC1 at pH 7.6, 5 
mmol/L EDTA, and 0.25 mol sucrose) and homoge- 
nized with five strokes of a "zero-clearance" homog- 
enizer (Model K886030; Kontes Co.). The membrane 
fraction was collected by centrifugation for 20 minutes 
at 43,000 x g. The pellet was resuspended in 10 ml 
TME buffer (50 mmol/L TrisC1 at pH 7.6, 10 mmol/ 
L MgC12, and 1 mmol/L EGTA), then washed three 
times by pelleting and resuspending in TME buffer. 
[31-1]Yohimbine binding (1 to 20 nmol/L) was measured 
in triplicate as described.' Nonspecific binding was 
determined in the presence of 10-s mol/L yohimbine. 
Scatchard plots of specific [3H]yohimbine binding were 
prepared and maximum binding (13max) and affinity (Kd) 
values were determined from linear least-squares fit of 
the data. 
Protocol. Subjects came to the laboratory at 8 AM. 
Height, weight, baseline pupil size, and forearm vol- 
ume were measured. Plastic catheters were placed in 
the left brachial artery and an adjacent vein. After 30 
minutes of supine rest, venous blood for plasma cate- 
cholamine, plasma renin activity, and platelet a2 re- 
ceptor determinations was drawn. Arterial pressures 
Study 1 Study 2 P value 
HR (bpm) 77 ± 14 63 ± 13 <0.001 
SBP (mm Hg) 135 ± 14 127 ± 13 <0.02 
DBP (mm Hg) 76 ± 9 67 ± 5 <0.001 
FABF (m1/100 ml fore- 
arm volume/min) 
4.7 -± 2.2 4.3 ± 1.6 0.71 
Plasma NE (pg/ml) 303 -± 107 170 ± 46 <0.01 
Plasma E (pg/ml) 79 ± 25 60 ± 24 0.07 
PRA (ng AI/ml/hr) 5.8 ± 3.9 4.6 ± 3.3 0.20 
Platelet a2-receptors 
(fmol/mg) 
204 ± 77 301 ± 150 <0.02 
VOLUME 38 
NUMBER 5 
60 - 
50 
20 
10 
Platelet a2-receptors 521 
100 200 300 400 
Specific [3H1 Yohimbine Binding lfrnole/mgl 
Fig. 2. Scatchard plot in one subject of [31-1]yohimbine binding 
to platelet membranes during the first study (diuretic alone; 
II) and the second study (diuretic with guanadrel; A). The 
(x-intercept) increased during guanadrel therapy from 
160 to 353 fmol/mg protein, while the K,, (affinity = slope) 
did not change. 
RESULTS 
In our 11 subjects, casual blood pressure at the first 
visit was 138 ± 13/89 ± 7 mm Hg, height was 
180 ± 7 cm, and weight was 210 ± 37 lb. Values for 
heart rate, intra-arterial blood pressure, forearm blood 
flow, plasma catecholamine levels, plasma renin activ- 
ity, and platelet a2-receptors after 30 minutes supine 
rest are listed in Table I. Addition of guanadrel lowered 
supine heart rate and intra-arterial systolic and diastolic 
pressures. Forearm blood flow did not change, and 
plasma norepinephrine levels were reduced. Although 
plasma renin activity and plasma epinephrine levels 
tended to fall, the differences were not statistically sig- 
nificant. 
Platelet a2-receptor number increased as determined 
by Scatchard plots of PH]yohimbine binding. Because 
two specimens were lost, complete data on platelet a2- 
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Fig. 1. Mean ( SE) and individual paired plasma norepi- 
nephrine (NE) and platelet etrreceptor values ([31-11yohimbine 
[Lax) are shown for subjects in study 1 (diuretics) and study 
1 (diuretic and guanadrel). Both the decrease in plasma nor- 
epinephrine level and the increase in platelet a.2-receptors were 
significant at P < 0.05. 
were monitored and measured by connecting the 
brachial cannula to a Hewlett-Packard Co. quartz 
transducer (1290 A), polygraph (4568 C), and oscil- 
loscope (1308 A) and a Gould Inc. thermal recorder 
(TA 600). 
After baseline supine measurements, a random order 
infusion of norepinephrine into the brachial artery was 
started at 0.005, 0.01, 0.02, 0.04, and 0.08 lig per 100 
ml forearm volume per minute. Each norepinephrine 
infusion lasted 4 minutes and was followed by an 11- 
minute infusion of saline solution. Arterial pressure and 
forearm blood flow were measured during the last min- 
ute of each norepinephrine infusion and at each baseline 
saline solution infusion period. One hour before the 
completion of the hemodynamic measurements, 40 p,1 
1% phenylephrine was instilled into the lower con- 
junctival sac of the right eye. The study ended with 
recording of pupil size. 
Statistical analysis. Data are reported as the 3-C 
SD. Comparisons of variables between the two studies 
were made by the paired t test. Statistical significance 
was defined by a P value <0.05. 
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Fig. 3. Group X ± SE of the percentage increase in forearm 
vascular resistance (A% FAVR) in response to five doses of 
intra-arterial norepinephrine (i.a. NE) given in random se- 
quence in study 1 (diuretics; A) and study 2 (diuretic with 
guanadrel; ). No significant differences were noted at any 
point on the dose-response curves when the two studies were 
compared. 
receptors were available for only nine subjects. As 
shown in Fig. 1, eight of the nine subjects showed an 
increase in Bma (P < 0.02), while 10 of 11 had a re- 
duction in norepinephrine levels (P < 0.01). The sub- 
ject with a decreased Bma during the guanadrel trial 
received the lowest dose of the drug, 5 mg twice a day, 
and was the only subject without a reduction in the 
plasma norepinephrine level. However, in the whole 
group we found no significant correlation between 
either the absolute (r = 0.39) or percentage (r = 
0.31) increase in a2-receptors and the reduction in 
plasma norepinephrine level. 
The amount of platelet protein recovered before and 
during guanadrel therapy was unchanged (3.2 ± 1.1 
vs 2.8 ± 1.4 mg). This suggests that the increase in 
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Fig. 4. The mydriatic response for each subject comparing 
studies 1 and 2 as shown in relationship to the line of identity. 
As shown, most of the points fell close to the line of identity. 
This suggests that acreceptor-mediated pupillary mydriasis 
did not change with addition of guanadrel. 
yohimbine binding was due to an increase in the number 
of binding sites rather than a decrease in the amount of 
protein recovered. While platelet arreceptor number 
increased, the Kd for yohimbine did not change during 
guanadrel therapy (5.4 ± 0.5 vs. 5.0 ± 0.8 nmol). 
Fig. 2 illustrates this increased Ba,a (x-intercept) with- 
out change in Kd (slope) in one subject. Guanadrel 
inhibited [31-11yohimbine binding at high concentrations, 
with half-maximal inhibition at 50 mmol/L. 
The percent forearm vasoconstrictor responses to lo- 
cally infused norepinephrine (Fig. 3) and the pupillary 
mydriatic response to 1% ophthalmic phenylephrine 
(Fig. 4) did not change. 
DISCUSSION 
Addition of guanadrel to diuretic therapy reduced 
supine heart rate and intra-arterial blood pressure. 
Guanadrel also reduced the supine baseline plasma nor- 
epinephrine level. These declines are probably ex- 
plained by the known ability of the drug to reduce 
noradrenaline storage in and release from the postgan- 
glionic sympathetic nerve terminal.' Platelet a2-recep- 
tor number increased significantly, presumably in re- 
sponse to the reduced sympathetic drive. The effect of 
guanadrel on platelet arreceptor number is not likely 
to be due to a direct interaction with the a2-receptors, 
because guanadrel inhibits [31-11yohimbine binding only 
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at very high concentrations (half-maximal inhibition at 
50 mmol/L; data not shown). Pupillary mydriasis and 
forearm vasoconstriction in response to exogenous a- 
agonists did not change. 
There are several salient findings of our study. First, 
plasma levels of norepinephrine, but not epinephrine, 
fell in response to a drug known to reduce sympathetic 
drive. The dissociation between the changes in the two 
measured catecholamines most likely reflects the post- 
ganglionic as opposed to central sympatholytic effects 
of guanadrel." There is extensive interest in the utility 
of venous plasma catecholamine levels for the assess- 
ment of sympathetic nervous system activity. It is 
evident that significant differences in regional release 
can occur without being reflected in the systemic venous 
catecholamine measurement.' It is also known that dif- 
ferences in reuptake between individuals may compli- 
cate interindividual comparisons:7 However, our data 
further substantiate the value of plasma norepinephrine 
levels as an index of intraindividual changes in sym- 
pathetic drive. 
Second, the increase in the number of platelet ar 
receptors during guanadrel therapy is of special interest. 
This is the first study in man to show a consistent 
increase in platelet arreceptors in response to a well- 
defined pharmacologic reduction of sympathetic drive 
and is in agreement with a similar study in rodents:8 
Patients with disease-related reduction in sympathetic 
drive such as idiopathic orthostatic hypotension have 
increased numbers of platelet a2-receptors." How- 
ever, in other studies surgical reduction of sympathetic 
stimulation by ablation of pheochromocytoma tissue 
has produced conflicting results of either no change2' 
or an increase' in platelet a2-receptors. Administration 
of the pharmacologic a2-agonists guanabenz and don- 
idine has also produced conflicting findings, showing 
either no change" or a decrease' in platelet a2-receptor 
number. While it is not clear precisely which factors 
regulate platelet a2-receptor number, it is not likely that 
circulating levels of plasma catecholamines are an 
overriding factor.2' '24 
Third, the functional measures of a-adrenergic re- 
sponsiveness, norepinephrine-induced forearm vaso- 
constriction, and phenylephrine-induced pupillary my- 
driasis did not change during guanadrel therapy (Figs. 
2 and 3). This is in contrast to the consistent decrease 
in plasma norepinephrine levels and increase in platelet 
a2-receptor number. These observations indicate that 
caution is needed when extrapolating from differences 
in or changes of in vitro biochemical measurements of 
sympathetic activity to in vivo physiologic significance. 
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The possible explanations for these apparent dis- 
crepancies are many However, we believe the most 
likely explanations are either that (1) the pupillary and 
vascular responses are largely a, effects and (xi-recep- 
tors may not upregulate as much as the platelet a2- 
receptors or (2) the diuretics blunted physiologic re- 
sponses to catecholamines ,25 perhaps by altering the 
intracellular environment.' Additional studies of re- 
sponses to a2-selective agonists in subjects not taking 
diuretics should answer these questions. 
In summary, addition of guanadrel to diuretic mono- 
therapy reduced blood pressure and heart rate in 11 
patients with essential hypertension. This reduction was 
accompanied by a reduction in sympathetic drive 
(plasma norepinephrine level) and an increase in platelet 
a2-receptors. Despite these changes, physiologic re- 
sponses to exogenous a-agonists did not change. Con- 
sequently, extrapolations from in vitro measurements 
of sympathetic activity to in vivo physiologic signifi- 
cance may be incorrect. There are many potential , ex- 
planations for this apparent dichotomy and they deserve 
further investigation. 
We are indebted to our technical and data analysis staff of 
J. Mertens, M. Elkins, D. Rogers, D. Brant, M. Rapai, L. 
Vadnay, N. Schork, Olga Szamraj, and Mark Zamorski. 
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